Laurion Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Laurion Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,530	Closed	-$132K	–	613
2023 Q3	$132K	Buy	+30,530	New	+$170K	﹤0.01%	441
2020 Q4	–	Sell	-30,900	Closed	-$298K	–	992
2020 Q3	$298K	Buy	+30,900	New	+$330K	﹤0.01%	673
2020 Q1	–	Sell	-14,800	Closed	-$243K	–	1115
2019 Q4	$243K	Sell	14,800 -19,300	-57%	-$292K	﹤0.01%	795
2019 Q3	$453K	Buy	34,100 +7,145	+27%	+$99.6K	﹤0.01%	784
2019 Q2	$380K	Buy	+26,955	New	+$429K	﹤0.01%	738
2018 Q4	–	Sell	-66,111	Closed	-$1.52M	–	1444
2018 Q3	$1.52M	Buy	+66,111	New	+$1.35M	0.01%	595
2018 Q2	–	Sell	-194,070	Closed	-$3.27M	–	1607
2018 Q1	$3.27M	Buy	+194,070	New	+$3.25M	0.03%	480

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Laurion Capital Management's VNDA Position: Q4 2023 in Review

Laurion Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 30,530 shares — an estimated $132K sold.

Laurion Capital Management first reported a position in VNDA in Q1 2018 and held it in 7 quarters. The position peaked at $3.27M in Q1 2018. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Laurion Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Laurion Capital Management sold 30,530 Vanda Pharmaceuticals shares in Q4 2023, an estimated $132K.
Laurion Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Laurion Capital Management's Vanda Pharmaceuticals position peaked at $3.27M in Q1 2018.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.